Theophylline
Theospirex is a medicine that contains theophylline, which has a bronchodilating effect on the smooth muscles of the bronchi, bronchioles, and blood vessels, and also inhibits the release of mediators from cells involved in inflammatory reactions.
The medicine also has a positive effect on the strength and duration of cardiac muscle contraction, as well as increasing urine excretion.
Theophylline should not be used as a first-line treatment for asthma in children.
Before starting treatment with Theospirex, you should discuss it with your doctor, pharmacist, or nurse:
The medicine should be used with caution during vaccination and in elderly patients.
Fever reduces the rate of theophylline elimination from the body. In the case of acute illness with fever, it may be necessary to reduce the dose to avoid toxicity.
Theospirex should not be used in children under 6 months old.
Detailed information on the use of the medicine in children and adolescents is presented in section 3. "How to use Theospirex".
You should tell your doctor or pharmacist about all medicines you are taking, have recently taken, or plan to take.
In particular, you should inform about the use of any of the following medicines, as Theospirex may change their effect and increase the risk of side effects:
A lower concentration of theophylline in the blood occurs in tobacco smokers.
In the case of taking medicines that affect theophylline concentration in serum, the dose should be adjusted accordingly.
You should inform about the use of medicines that may enhancethe effect of Theospirex and increase the risk of its side effects:
Alcohol causes an increase in theophylline concentration in the blood, so you should not consume alcoholic beverages while taking Theospirex.
You should inform about the use of medicines that may weakenthe effect of Theospirex and reduce its effectiveness:
A diet low in carbohydrates (sugars) and high in protein, as well as parenteral nutrition, and consuming large amounts of grilled beef can reduce the amount of theophylline in the body and weaken its effect.
A diet high in carbohydrates and low in protein may lead to an increase in the amount of theophylline in the body, enhancement of its effect, and an increased risk of side effects.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, you should consult your doctor or pharmacist before using this medicine.
Pregnancy
The safety of theophylline use during pregnancy has not been established, as no adequate studies have been conducted.
Theophylline crosses the placental barrier and may cause side effects in the fetus.
Theophylline should not be used during pregnancy, especially in the first three months, unless it is absolutely necessary. In the second and third trimesters of pregnancy, theophylline can be used only when the benefits to the mother outweigh the risks to the fetus.
The degree of theophylline binding to plasma proteins and clearance may decrease during pregnancy. It may be necessary to reduce the dose to avoid side effects.
The use of theophylline in late pregnancy may inhibit uterine contractions. It is recommended to closely monitor newborns exposed to theophylline in late pregnancy to detect any possible objective symptoms caused by its effects.
Breastfeeding
You should not use the medicine during breastfeeding.
Theophylline passes into breast milk and during breastfeeding may cause side effects in breastfed infants. Its concentration in breast milk of a nursing mother may be 60-90% of the concentration of this medicine in the blood.
Theophylline may affect your ability to drive and use machines. You should be careful, due to the possibility of drowsiness and dizziness.
Each 10 ml ampoule contains 1.19 mmol (or 27.31 mg) of sodium. This should be taken into account in patients with reduced renal function and in patients on a controlled sodium diet.
This medicine should always be used as directed by your doctor. If you are unsure, you should consult your doctor, pharmacist, or nurse.
Theospirex can be administered intravenously:
The therapeutic concentration of theophylline in serum is 10 to 20 µg/ml (56 to 112 µmol/l).
Theophylline at a concentration higher than 20 µg/ml (112 µmol/l) may be toxic.
Due to large individual differences in theophylline pharmacokinetics and the narrow therapeutic range, the medicine should be dosed individually.
Theophylline concentration in serum should be monitored.
This recommendation is particularly important in cases where there is an increased risk of exceeding the therapeutic concentration, such as when changing the dose or changing the type of preparation used. Theospirex for intravenous administration contains theophylline as the active substance, and commonly used theophylline for intravenous administration in other medicines is usually in the form of a combination with ethylenediamine (as so-called aminophylline). Although the pharmacokinetic profile of both medicines administered in equivalent (in terms of theophylline) doses seems to be similar, it cannot be ruled out that changing one medicine to another may result in achieving theophylline concentrations that are slightly different from those occurring during previous therapy, therefore, after changing the medicine, it is recommended to determine the theophylline concentration.
The dose should be calculated based on the lean body mass (fat tissue in children accounts for 12%, in adults 22%), as theophylline is not distributed to fatty tissue. Theophylline can be administered in intermittent or continuous intravenous infusion at a rate of 5 to 10 mg/minute, for a period of not less than one hour. Theophylline should not be administered at a rate greater than 25 mg/minute.
The required theophylline concentration, achieved after administration of the initial dose, is maintained by means of a maintenance dose based on the current theophylline concentration in the blood serum.
The total dose (the dose refers to anhydrous theophylline - 1 ampoule = 200 mg of anhydrous theophylline) should be determined according to the following scheme:
Patients not previously treated with theophylline:
Initial dose | Theophylline dose iv. /kg body weight |
Without prior theophylline treatment |
|
In case of suspected or proven prior theophylline treatment |
|
Patients not currently receiving other theophylline-containing medicines:
Patient group | Initial dose [mg/kg body weight/h] | Dose for the first 12 hours [mg/kg body weight/h] | Maintenance dose during treatment above 12 hours [mg/kg body weight/h] |
Children aged 6 months to 9 years Children aged 10 to 16 years and adults who have recently started smoking Non-smoking adults without concomitant diseases Patients with congestive heart failure, liver failure Other patients, including those with right ventricular hypertrophy | 5 5 5 5 5 | 1.0 0.85 0.6 0.4 0.5 | 0.85 0.7 0.43 0.1 0.26 |
In the absence of the possibility of controlling the drug concentration in the blood, the daily dose should not be exceeded, which should be calculated according to the following scheme:
Patient groups
Maximum daily dose
Children aged 2 to 9 years
24 mg/kg body weight, not more than 900 mg
Children aged 10 to 12 years
20 mg/kg body weight, not more than 900 mg
Children aged 13 to 16 years
18 mg/kg body weight, not more than 900 mg
Adults and adolescents over 16 years
13 mg/kg body weight, not more than 900 mg
Children under 6 months
Theospirex should not be used in children under 6 months.
Intravenous injection
Administer slowly, over at least 6 minutes, into a sufficiently large vein.
Short intravenous infusion
Administer intravenously over 20-30 minutes, in 50-100 ml of an appropriate infusion solution.
Intravenous drip infusion
Administer in 250 ml of an appropriate infusion solution. The duration of the infusion can be determined according to the above dosage scheme. However, it can be modified according to individual needs.
In the treatment of small children, it is necessary to consider the need to reduce the volume of fluids administered in the infusion.
After injection or infusion, the patient should remain at rest for a short time, under supervision. If there is information about previous administration of methylxanthine-containing drugs or if such administration is suspected, the injection or infusion should be performed under special supervision, and if intolerance occurs, it should be discontinued.
The duration of treatment depends on the type, severity, and course of the disease and is determined by the attending physician.
Symptoms of overdose
Symptoms of theophylline overdose may occur if its concentration in the blood serum is higher than 20 μg/ml, and they worsen with higher concentrations.
Usually, tachycardia (rapid heart rate) occurs first, followed by gastrointestinal symptoms (nausea, vomiting, vomiting with blood, stomach pain, diarrhea), central nervous system stimulation (anxiety, headaches, insomnia, dizziness), excessive thirst, tinnitus, palpitations, and arrhythmias. Excessive sweating and muscle tremors may occur.
In the case of significant overdose (theophylline concentration in the blood is higher than 25 µg/ml), seizures, circulatory failure, hyperthermia (increased body temperature), severe arrhythmias, including ventricular arrhythmias, and even cardiac arrest and death may occur.
In patients with increased sensitivity to theophylline, severe overdose symptoms may occur even when the theophylline concentration in the blood is less than 20 µg/ml.
Procedure in case of overdose
In the case of mild overdose symptoms:
You should stop administering the medicine and determine the theophylline concentration in the blood. If treatment is resumed, the dose should be reduced accordingly.
If symptoms from the central nervous system occur (e.g., anxiety and seizures):
If overdose symptoms are potentially life-threatening, you should:
In the case of life-threatening arrhythmias:
In patients with bronchial asthma, propranolol may cause severe bronchospasm, so in these patients, verapamil should be administered instead of propranolol.
In very severe cases of poisoning, when the above procedure is ineffective, and in patients with very high theophylline concentrations in the blood, rapid and complete detoxification can be achieved through hemoperfusion or hemodialysis. In most cases, this is not necessary, as theophylline is metabolized sufficiently quickly.
You should not take a double dose to make up for a missed dose.
If you have any further doubts about using this medicine, you should consult your doctor or pharmacist.
Like all medicines, Theospirex can cause side effects, although not everybody gets them.
During treatment with Theospirex, the following side effects may occur:
Gastrointestinal disorders:
Very common (in more than 1 in 10 patients): irritation of the mucous membrane of the digestive tract, nausea, vomiting, stomach pain, diarrhea, loss of appetite, anorexia. There have been reports of bloody vomiting after theophylline. Existing gastroesophageal reflux may worsen at night due to the relaxation of the esophageal sphincter.
Nervous system and psychiatric disorders:
Very common (in more than 1 in 10 patients): central nervous system stimulation; headaches, irritability, anxiety, insomnia, dizziness, increased reflexes, muscle tremors, and seizures.
Cardiac disorders:
Very common (in more than 1 in 10 patients): arrhythmias, rapid heart rate, extra beats, and ventricular arrhythmias, palpitations.
Respiratory, thoracic, and mediastinal disorders:
Very common (in more than 1 in 10 patients): rapid breathing.
Vascular disorders:
Very common (in more than 1 in 10 patients): decreased blood pressure.
Renal and urinary disorders:
Very common (in more than 1 in 10 patients): increased urine production due to the diuretic effect of theophylline, proteinuria, and hematuria may occur. There have also been reports of the syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Immune system disorders:
Uncommon (in less than 1 in 100, but more than 1 in 1,000 patients): hypersensitivity reactions, urticaria, generalized itching, angioedema - allergic reactions, such as skin and mucous membrane reactions, and sudden swelling of the skin and mucous membranes (e.g., throat or tongue), difficulty breathing, and (or) itching and rash.
Investigations:
Very common (in more than 1 in 10 patients): increased glucose concentration in the blood serum, (decreased potassium concentration in the blood), increased creatinine concentration in the blood serum, changes in electrolyte concentrations in the blood, increased uric acid concentration in the blood.
Side effects may be more severe in people with hypersensitivity to theophylline or in the case of overdose (theophylline concentration in the blood higher than 20 mg/l).
In particular, when the theophylline concentration in the blood is higher than 25 mg/l, toxic effects may occur, such as seizures, sudden drop in blood pressure, ventricular arrhythmias, and severe gastrointestinal symptoms (including gastrointestinal bleeding).
If you experience any side effects, including any side effects not listed in the leaflet, you should tell your doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, Tel: +48 22 49 21 301, Fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl
By reporting side effects, you can help gather more information on the safety of the medicine.
The medicine should be stored out of sight and reach of children.
There are no special recommendations for storage temperature.
Store in the original packaging to protect from light.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month stated.
Medicines should not be disposed of via wastewater or household waste. You should ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Theospirex is a colorless and clear solution.
The medicine is packaged in type I glass ampoules, containing 10 ml of the solution, and placed in a cardboard box.
The package contains 5 ampoules of 10 ml of the solution.
For more detailed information, you should contact the marketing authorization holder or the parallel importer.
Gebro Pharma GmbH
Bahnhofbichl 13
6391 Fieberbrunn
Austria
Gebro Pharma GmbH
Bahnhofbichl 13
6391 Fieberbrunn
Austria
Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
Marketing authorization number in Austria, the country of export:1-18867
[Information about the trademark]
---------------------------------------------------------------------------------------------------------------------------
Information intended only for healthcare professionals:
In the case of mixing Theospirex with another solution, you should pay special attention to any discoloration, clouding, or precipitation in the resulting solution.
Theospirex can be mixed with the following solutions:
The medicine should not be mixed with other solutions if their chemical compatibility with theophylline has not been tested.
Solvents for theophylline should not be mixed directly in the same syringe, as they may cause precipitation or chemical changes in the resulting solution.
It should also be remembered that theophylline interacts with other medicines.
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.